Dhebaria T, et al. - Via this prospective, randomized, double‐blind placebo‐controlled trial, researchers examined whether intravenous (IV) acetaminophen can aid in decreasing the amount of opioid medication provided to pediatric patients with sickle cell disease (SCD) having a vaso‐occlusive crisis (VOC) in an emergency department (ED) setting. They randomized 71 patients with SCD, aged 4‐16 years, with VOC pain either to the acetaminophen group comprising of 35 patients or to the placebo group comprising of 36 patients. No reduction in the requirement for morphine was observed among patients who received IV acetaminophen vs those in the placebo group. In addition, the 2 groups were equivalent in disposition pain scores. The findings overall suggest that the use of IV acetaminophen in addition to morphine for pediatric sickle cell VOC pain provides no opioid-sparing effect.